The Phase III failure of the combination of Incyte Corp.'s IDO inhibitor epacadostat and Merck & Co. Inc.'s Keytruda in melanoma represents another knock on the new immuno-oncology class, raising uncertainty about prospects for other IDO candidates in development.
Epacadostat is the most advanced inhibitor of indoleamine 2,3-dioxygenase 1 (IDO1), an enzyme on the tumor microenvironment that plays an important role in immune response. Bristol-Myers Squibb Co
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?